Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.55 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | TACR2 | P21452 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SHBG | P04278 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5545488 | 0.98 | CYP4Z1 (0.59) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL5544355 | 0.98 | CYP4Z1 (0.59) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL11615189 | 0.98 | CYP4Z1 (0.59) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL5050631 | 0.95 | CYP4F2 (0.60) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL9671800 | 0.91 | CYP4Z1 (0.65) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL14570534 | 0.88 | CYP4Z1 (0.62) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL304455 | 0.88 | CYP4F2 (0.74) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL10289901 | 0.87 | CYP4Z1 (0.60) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL5542104 | 0.87 | CYP4Z1 (0.60) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 | |
| SCHEMBL6204525 | 0.87 | CYP4Z1 (0.60) | CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524362-A | Malachite green artificial antigen and antibody, and preparation method and application thereof | UNIV SHENZHEN | 2014-01-22 | — | — | CN | claimed |
| CN-103524362-B | Malachite green artificial antigen and antibody and its preparation method and application | SHENZHEN UNIVERSITY (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| CN-103524362-A | Malachite green artificial antigen and antibody, and preparation method and application thereof | UNIV SHENZHEN | 2014-01-22 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-1997000249-A1 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-03 | — | — | WO | disclosed |
| EP-0625981-A1 | AZABICYCLO COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993015080-A1 | AZABICYCLO COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
| CN-1071423-A | BICYCLIC CARBOXYLIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 1993-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP4Z1 1854/4885CYP4F2 954/4885CYP4A11 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.